Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03998033 · ClinicalTrials.gov registry record · Phase 1
Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma
A Phase 1 study, sponsored by Eureka Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT03998033: Clinical Trial Phase 1 study, sponsored by Eureka Therapeutics.
NCT03998033 is a Phase 1 study that was terminated before completion, run by Eureka Therapeutics. The registered enrollment target is 2 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03998033, a Phase 1 study, was terminated before completion, sponsored by Eureka Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This is a open-label, dose escalation, multi-center, Phase I / Phase II study to assess the safety of an autologous T-cell product (ET140202) in adult subjects with advanced Alpha-fetoprotein (AFP) positive/Human Leukocyte Antigen (HLA) A-2 positive Hepatocellular Carcinoma (HCC).
Primary Outcome
Safety and tolerability of ET140202 T cells as assessed by committee review of dose limiting toxicities (DLTs) and incidence and severity of adverse events (AEs) after infusion
Interventions
- BIOLOGICAL ET140202 autologous T cell product
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2019-05-30 |
| Est. Completion | 2020-12-31 |
| Phase | Phase 1 |
Why NCT03998033 stopped before completion
NCT03998033 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which ET140202 autologous T cell product is the first listed.
NCT03998033 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03998033 about?
NCT03998033 is a clinical study titled "Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma". This is a open-label, dose escalation, multi-center, Phase I / Phase II study to assess the safety of an autologous T-cell product (ET140202) in adult subjects with advanced Alpha-fetoprotein (AFP) positive/Human Leukocyte Antigen (HLA) A-2 positive Hepatocellular Carcinoma (HCC).
What is the current status of trial NCT03998033?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2019-05-30. Estimated completion is 2020-12-31.
What interventions are being tested in trial NCT03998033?
The interventions under investigation include: ET140202 autologous T cell product (BIOLOGICAL).
Who is sponsoring clinical trial NCT03998033?
This trial is sponsored by Eureka Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03998033's enrollment target sits among peer trials
2 2000th of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI